Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 4/2009

01-04-2009 | Original Article

Respiration-averaged CT for attenuation correction in non-small-cell lung cancer

Authors: Nai-Ming Cheng, Chih-Teng Yu, Kung-Chu Ho, Yi-Cheng Wu, Yuan-Chang Liu, Chih-Wei Wang, Tzu-Chen Yen

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 4/2009

Login to get access

Abstract

Purpose

Breathing causes artefacts on PET/CT images. Cine CT has been used to reduce respiratory artefacts by acquiring multiple images during a single breathing cycle. The aim of this prospective study in non-small-cell lung cancer (NSCLC) patients was twofold. Firstly, we sought to compare the motion artefacts in PET/CT images attenuation-corrected with helical CT (HCT) and with averaged CT (ACT), which provides an average of cine CT images. Secondly, we wanted to evaluate the differences in maximum standardized uptake values (SUVmax) between HCT and ACT.

Methods

Enrolled in the study were 80 patients with NSCLC. PET images attenuation-corrected with HCT (PET/HCT) and with ACT (PET/ACT) were obtained in all patients. Misregistration was evaluated by measurement of the curved photopenic area in the lower thorax of the PET images for all patients and direct measurement of misregistration for selected lesions. SUVmax was measured separately at the primary tumours, regional lymph nodes, and background.

Results

A total of 80 patients with NSCLC were included. Significantly lower misregistrations were observed in PET/ACT images than in PET/HCT images (below-thoracic misregistration 0.25±0.58 cm vs. 1.17±1.17 cm, p<0.001; lesion misregistration 1.38±2.10 vs. 3.10±4.09, p=0.013). Significantly higher SUVmax were noted in PET/ACT images than in PET/HCT images in the primary tumour (p<0.001) and regional lymph nodes (p<0.001). Compared with PET/HCT images, the magnitude of SUVmax in PET/ACT images was higher by 0.35 for the main tumours and 0.34 for lymph nodes.

Conclusion

Due to its significantly reduced misregistration, PET/ACT provided more reliable SUVmax and may be useful in treatment planning and monitoring the therapeutic response in patients with NSCLC.
Literature
1.
Shepherd FA, Rodrigues PJ, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123–32.PubMedCrossRef
2.
Lilenbaum R, Axelrod R, Thomas S, et al. Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2. J Clin Oncol 2008;26:863–9.PubMedCrossRef
3.
van Tinteren H, Hoekstra OS, Smit EF, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet 2002;359:1388–93.PubMedCrossRef
4.
Pieterman RM, van Putten JW, Meuzelaar JJ, et al. Preoperative staging of non-small-cell lung cancer with positron emission tomography. N Engl J Med 2000;343:254–61.PubMedCrossRef
5.
Eschmann SM, Friedel G, Paulsen F, et al. Repeat (18)F-FDG PET for monitoring neoadjuvant chemotherapy in patients with stage III non-small cell lung cancer. Lung Cancer 2007;55:165–71.PubMedCrossRef
6.
Yamamoto Y, Nishiyama Y, Monden T, et al. Correlation of FDG-PET findings with histopathology in the assessment of response to induction chemoradiotherapy in non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2006;33:140–7.PubMedCrossRef
7.
Weber WA, Petersen V, Schmidt B, et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 2003;21:2651–7.PubMedCrossRef
8.
Choi NC, Fischman AJ, Niemierko A, et al. Dose-response relationship between probability of pathologic tumor control and glucose metabolic rate measured with FDG PET after preoperative chemoradiotherapy in locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2002;54:1024–35.PubMedCrossRef
9.
MacManus MP, Hicks RJ, Matthews JP, et al. Metabolic (FDG-PET) response after radical radiotherapy/chemoradiotherapy for non-small cell lung cancer correlates with patterns of failure. Lung Cancer 2005;49:95–108.CrossRef
10.
MacManus MP, Hicks RJ, Matthews JP, et al. Positron emission tomography is superior to computed tomography scanning for response assessment after radical radiotherapy/chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol 2003;21:1285–92.CrossRef
11.
Eschmann SM, Friedel G, Paulsen F, et al. (18)F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2007;34:463–71.PubMedCrossRef
12.
Hellwig D, Graeter TP, Ukena D, et al. Value of F-18-fluorodeoxyglucose positron emission tomography after induction therapy of locally advanced bronchogenic carcinoma. J Thorac Cardiovasc Surg 2004;128:892–9.PubMedCrossRef
13.
Kong FMS, Frey KA, Quint LE, et al. A pilot study of [18F]Fluorodeoxyglucose positron emission tomography scans during and after radiation-based therapy in patients with non-small-cell lung cancer. J Clin Oncol 2007;25:3116–23.PubMedCrossRef
14.
Goerres GW, Burger C, Kamel E, et al. Respiration-induced attenuation artifact at PET/CT: technical considerations. Radiology 2003;226:906–10.PubMedCrossRef
15.
Goerres GW, Kamel E, Heidelberg TN, et al. PET-CT image co-registration in the thorax: influence of respiration. Eur J Nucl Med Mol Imaging 2002;29:351–60.PubMedCrossRef
16.
Cohade C, Osman M, Marshall LN, et al. PET-CT: accuracy of PET and CT spatial registration of lung lesions. Eur J Nucl Med Mol Imaging 2003;30:721–6.PubMed
17.
Osman MM, Cohade C, Nakamoto Y, et al. Clinically significant inaccurate localization of lesions with PET/CT: frequency in 300 patients. J Nucl Med 2003;44:240–3.PubMed
18.
Erdi YE, Nehmeh SA, Pan T, et al. The CT motion quantitation of lung lesions and its impact on PET-measured SUVs. J Nucl Med 2004;45:1287–92.PubMed
19.
Pan T, Mawiawi O, Nehmeh SA, et al. Attenuation correction of PET images with respiration-averaged CT images in PET/CT. J Nucl Med 2005;46:1481–7.PubMed
20.
Nehmeh SA, Erdi YE, Pan T, et al. Quantitation of respiratory motion during 4D-PET/CT acquisition. Med Phys 2004;31:1333–8.PubMedCrossRef
21.
Pan T, Lee TY, Rietzel E, Chen GTY. 4D-CT imaging of a volume influenced by respiratory motion on multi-slice CT. Med Phys 2004;31:333–40.PubMedCrossRef
22.
Pan T, Mawlawi O, Luo D, Liu HH, et al. Attenuation correction of PET cardiac data with low-dose average CT in PET/CT. Med Phys 2006;33:3931–8.PubMedCrossRef
23.
Gould KL, Pan T, Loghin C, Johnson NP, Guha A, Sdringola S. Frequent diagnostic errors in cardiac PET/CT due to misregistration of CT attenuation and emission PET images: a definitive analysis of causes, consequences, and corrections. J Nucl Med 2007;48:1112–21.PubMedCrossRef
24.
Alessio AM, Kohlmyer S, Branch K, Chen G, Caldwell J, Kinahan P. Cine CT for attenuation correction in cardiac PET/CT. J Nucl Med 2007;48:794–801.PubMedCrossRef
25.
Cook RA, Carnes G, Lee TY, Wells RG. Respiration-averaged CT for attenuation correction in canine cardiac PET/CT. J Nucl Med 2007;48:811–8.PubMedCrossRef
26.
Chi PC, Mawlawi O, Nehmeh SA, et al. Design of respiration averaged CT for attenuation correction of the PET data from PET/CT. Med Phys 2007;34:2039–47.PubMedCrossRef
27.
Mountain CF, Dresler CM. Regional lymph node classification for lung cancer staging. Chest 1997;111:1718–23.PubMedCrossRef
28.
Nehmeh SA, Erdi YE. Respiratory motion in positron emission tomography/computed tomography: a review. Semin Nucl Med 2008;38:167–76.PubMedCrossRef
Metadata
Title
Respiration-averaged CT for attenuation correction in non-small-cell lung cancer
Authors
Nai-Ming Cheng
Chih-Teng Yu
Kung-Chu Ho
Yi-Cheng Wu
Yuan-Chang Liu
Chih-Wei Wang
Tzu-Chen Yen
Publication date
01-04-2009
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 4/2009
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-008-0995-7

Other articles of this Issue 4/2009

European Journal of Nuclear Medicine and Molecular Imaging 4/2009 Go to the issue

Original Article

Kinetic modelling of [11C]flumazenil using data-driven methods

Original Article

Quantification of (R)-[11C]PK11195 binding in rheumatoid arthritis

Original Article

Agreement and disagreement between contrast-enhanced magnetic resonance imaging and nuclear imaging for assessment of myocardial viability

Image of the Month

Functional neuroimaging in Hashimoto’s encephalitis: a physiopathological imaging?

Review Article

Nuclear imaging in cardiac amyloidosis

Original Article

Cancer-associated stroma affects FDG uptake in experimental carcinomas. Implications for FDG-PET delineation of radiotherapy target